ClinicalTrials.gg
RecruitingNCT07392177LOCUSleepUpdated Aug 19, 2026

Understanding the Role of the Locus Coeruleus in Insomnia

A Phase 2 interventional study of Dexmedetomidine and Placebo in Insomnia, sponsored by Woolcock Institute of Medical Research. Recruiting at 1 site in Australia. Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by Woolcock Institute of Medical Research · Phase 2, Interventional, and Other

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
30 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing dexmedetomidine in Sleep Initiation and Maintenance Disorders — 1 open to participants now, 1 under way, none of them phase 3. Dexmedetomidine · Sleep Initiation and Maintenance Disorders.

Planned enrollment
9th of 12
15 · median 72
Started
2026
the only one that year
Phase 2
Only one
of the 12
Registered
12th of 12
by date
Lead sponsor
1 of 12
Woolcock Institute of Medical Research

Among the 12 studies testing dexmedetomidine in Sleep Initiation and Maintenance Disorders, this one is the 9th largest by planned enrollment, is the only one that started in 2026, is the only one in phase 2, and was the 12th registered.

Sleep Initiation and Maintenance Disorders

2,728 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 731 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

1 of the 12 studies testing dexmedetomidine in Sleep Initiation and Maintenance Disorders is open now, in 1 country.

By country, each count listing its studies:

Where they have run

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 390 Sleep Initiation and Maintenance Disorders studies recruiting now, 153 (39%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 109 take healthy volunteers.

This study: 30 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing dexmedetomidine in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

This research project aims to better understand the neurobiological mechanistic underpinnings of insomnia disorder. The main question is whether cortical hyperarousal in individuals with insomnia disorder, measured by electroencephalograhic (EEG) infraslow oscillation coupling of sigma power during non-rapid eye movement (NREM) sleep and theta power during rapid eye movement (REM) sleep, is related to locus coeruleus activity.

Read the detailed description

This trial is a double-blinded, placebo-controlled, randomised controlled cross over trial of dexmedetomidine or placebo in adults with insomnia disorder. Participants will be recruited using social media, bulletin boards and patient referrals from the Woolcock Institute of Medical Research clinics. Participants will be asked to complete an online pre-screening webpage (RedCap) to check for eligibility, and provided with the Participant Information Sheet (PIS) and asked for contact details for an in-person screening visit. The participants will have the study explained in detail during the screening visit followed by written informed consent. The participant will then undergo a medical screening for diagnosis of insomnia disorder and the medical officer will sign the consent form. Thereafter, the participant will complete baseline questionnaires and be randomised to either dexmedetomidine or placebo for the 2 sleep laboratory visits. Participants will then be instructed to maintain their regular sleep-wake patterns for seven days before the first sleep laboratory visit (Visit 1). During Visit 1, participants will undergo a number of assessments (pre-sleep locus coeruleus activity measured using pupillometry, electroencephalography (EEG), functional near-infrared spectroscopy (fNIRS) before and during sleep and questionnaires about subjective hyperarousal. Participants will receive either dexmedetomidine or placebo. Following Visit 1, participants will have a 14-day washout, before Visit 2, which will repeat the procedures of Visit 1, but participants will receive the alternate condition (placebo or dexmedetomidine). The study will be coordinated from the Woolcock Institute of Medical Research, Sydney, Macquarie University, NSW, 2113, Australia.

03

Conditions studied

  • Insomnia

Keywords

  • Electroencephalography
  • Sleep
  • Locus coeruleus
  • Hyperarousal
04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of insomnia disorder ()
  • Insomnia severity index (ISI) score ≥15
  • Able to provide
  • Fluent English literacy

Exclusion criteria

Exclusion Criteria:

  • Medically diagnosis of sleep disordered breathing (i.e. sleep apnea) or sleep or circadian disorder other than insomnia
  • Uncontrolled psychiatric disorders
  • High dependence on medical care
  • History of, or current suicide ideation (Patient Health Questionnaire (PHQ-9) questionnaire)
  • Pregnancy or actively trying to conceive, or lactating
  • Shiftwork - defined as work outside of business hours (before 8am or after 6pm) conducted at least once per week
  • Travel across time zones of over 2 h time difference in the past week
  • Contraindicate the patient's participation in the clinical trial due to safety concerns or compliance with clinical study procedures
  • Concomitant use of medicines that are inhibitors, or moderate to strong inducers, of ; regular use of hypnotics and other medications that can cause additive sedation or psychostimulants or non-amphetamine psychostimulants within 14 days of starting the clinical trial
  • Ongoing use of THC- or CBD-containing products; dependence or any other drug or alcohol dependence
  • Allergy to lactose
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Dexmedetomidine

    A 96 µg dexmedetomidine tablet taken during the sleep laboratory visit only

    Drug: Dexmedetomidine

  • Active comparator
    Placebo

    Matching placebo tablet taken during the sleep laboratory visit only

    Drug: Placebo

Interventions

  • A buccal tablet containing 96 µg dexmedetomidine will be taken before habitual bedtime.

  • DrugPlacebo

    Placebo tablets will contain identical excipient without the active ingredient (dexmedetomidine) and manufactured under the same condition as the active. Placebo tablets, packs and instructions will be identical in every respect to enable the double-blind study design.

06

What researchers measure

Primary outcomes

  1. Electrographic (EEG) signatures

    Electrographic (EEG) infraslow oscillations (\~50 sec) of sigma power and sleep spindle coupling during non-rapid eye movement (NREM) sleep and theta power during rapid eye movement (REM) sleep.

    Time frame: Baseline and 14 days

Secondary outcomes

  1. Sleep Fragmentation

    Polysomnography (PSG) measure conducted during the intervention and control (wake after sleep onset)

    Time frame: Baseline and 14 days

  2. EEG power

    Electroencephalographic (EEG) power during non-rapid eye movement (NREM) (stages 2 and 3) and rapid eye movement (REM) sleep. Unit of measurement is μV\^2.

    Time frame: Baseline and 14 days

  3. Neurovascular activity (fNIRS)

    Measurement of global blood flow using functional near-infrared spectroscopy (fNIRS).

    Time frame: Baseline and 14 days

  4. Cardiopulmonary Coupling (CPC)

    Cardiopulmonary coupling provides a global measure of autonomic function

    Time frame: Baseline and 14 days

  5. Pupillometry

    Pupil sizes will be assessed as a surrogate of locus coeruleus activity

    Time frame: Baseline and 14 days

  6. Subjective hyperarousal

    Pre-Sleep Arousal Scale (PSAS) before sleep. Scored by summing 16 items (rated 1 (not at all) to 5 (extremely)) with a total score between 16 to 80

    Time frame: Baseline and 14 days

  7. Subjective sleep quality

    Self-reported rating of sleep quality (0-9) with higher scores indicating worse sleep. This will assessed in the morning after the overnight sleep study.

    Time frame: Baseline and 14 days

07

Study locations

1 of 1 sites recruiting
  • Woolcock Institute of Medical Research
    Macquarie Park, New South Wales 2113, Australia
    Recruiting
    • Greg Kaplan, PhD · Contactgrigori.kaplan@woolcock.org.au · +61 2 9805 3232
    • Christopher Gordon, PhD · Principal investigator
    • Brendon Yee, MBChB, PhD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — Non-identifiable IPD will be shared upon reasonable request to the Principal Investigators.

Supporting information: Study protocol, Informed consent form, Analytic code

Time frame: Non-identifiable IPD will become available one year after the Actual Study Completion Date and will be available for ten years.

Access criteria: A copy of the non-identifiable dataset may be requested by academic collaborators not affiliated with the Woolcock Institute of Medical Research through a data request form which outlines the investigators, aims and hypotheses, data to be included, a statistical analysis plan, ethics approval, and security measures. Contact the Coordinating Principal Investigator for access to data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Mar 2027, 7 months after the start.

Of 63 phase 2 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's planned 7 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 8, 2025
First posted
Feb 6, 2026
StartActual
Aug 12, 2026
Primary completionEst.
Mar 2027
CompletionEst.
Mar 2027
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07392177
Lead sponsor
Woolcock Institute of Medical Research
Responsible party
Christopher Gordon (Research Leader, Woolcock Institute of Medical Research) — Principal investigator
First posted
Feb 6, 2026
Start date
Aug 12, 2026
Primary completion
Mar 2027 (estimated)
Completion
Mar 2027 (estimated)
Last update
Aug 19, 2026

Study contacts

Christopher Gordon, PhD
Contact
c.gordon@mq.edu.au
+61 2 9805 3096
Camilla Hoyos, PhD
Contact
camilla.hoyos@mq.edu.au
Christopher Gordon, PhD
principal investigator · Woolcock Institute of Medical Research
Brendon Yee, MBChB, PhD
principal investigator · Woolcock Institute of Medical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion